MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
Craig-Hallum 22nd Annual Institutional Investor Conference | Minneapolis, MN
1:1 sessions: Wednesday, May 28, 2025
Goldman Sachs 46th Annual Global Healthcare Conference | Miami, FL
1:1 sessions: Wednesday, June 11, 2025
Northland Capital Growth Conference | Virtual
1:1 sessions: Wednesday, June 25, 2025
Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum, Goldman Sachs or Northland representative.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.18 |
| Daily Change: | 0.01 0.14 |
| Daily Volume: | 396,527 |
| Market Cap: | US$1.060B |
July 30, 2025 May 05, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
